Annex 1 at the transfer point: how to meet the evolving evidence challenge

Published: 3-Jul-2026

As Annex 1 raises expectations for contamination control, transfer-point evidence must become more dynamic, connected and defensible throughout the entire product lifecycle

You need to be a subscriber to read this article.
Click here to find out more.

In aseptic pharmaceutical manufacturing, the transfer point is where the process is at its most concentrated and its most exposed.

Two controlled environments meet, a connection is made, materials move and the connection is broken … all within seconds.

In that brief window, mechanical, microbial and procedural variables converge simultaneously, placing both product quality and operator safety at risk.

EU GMP Annex 1 identifies this moment as one of the highest contamination risks in the entire process, and rightly so.

Jonathan Bardsley, Head of Containment and Aseptic Process Technologies at ChargePoint Technology, reports. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like